<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823745</url>
  </required_header>
  <id_info>
    <org_study_id>A8121013</org_study_id>
    <nct_id>NCT00823745</nct_id>
  </id_info>
  <brief_title>Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects</brief_title>
  <official_title>A Phase 1 Study To Evaluate The Metabolism And Excretion Of [14C] PF-00868554 In Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study to assess the routes of elimination of a single oral dose of [14C]
      PF-00868554 and to characterize the metabolic profile following single dose administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The amount of radioactivity recovered in urine and feces, as a percent of the dose.</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The amount of PF-00868554, expressed as a percent of total radioactivity, in plasma, urine, and feces.</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification and determination of relative abundance of the metabolites of PF-00868554 in plasma, urine, and feces.</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters: AUClast, AUCinf, maximum concentration (Cmax), time of maximum concentration (Tmax), and half-life (t1/2) to describe the single dose PK of a) total radioactivity in blood; b) total radioactivity in plasma; c) PF-00868554 in plasma.</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints including adverse events, clinical laboratory tests, vital signs and ECGs.</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[14C]-PF-00868554</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-PF-00868554</intervention_name>
    <description>solution, single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, healthy volunteers.

        Exclusion Criteria:

          -  Females.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8121013&amp;StudyName=Radiolabel%20ADME%20%28Absorption%2C%20Distribution%2C%20Metabolism%2C%20and%20Excretion%29%20Study%20Of%20%5B14C%5D%20PF-00868554%20In%20Healthy%20Adult%20Male%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <last_update_submitted>March 6, 2009</last_update_submitted>
  <last_update_submitted_qc>March 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

